Clinical trials: Rectum Carcinoma
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
This clinical trial studies if enhanced outpatient symptom management with telemedicine and remote monitoring can help reduce acute care visit due to chemotherapy-related adverse events.
- Conditions
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT05038254
- Testing
- Best Practice, Patient Monitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Colon Cancer, Recurrent Rectal Cancer
Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy
This pilot clinical trial studies short-infusion ziv-aflibercept in treating patients with metastatic colorectal cancer receiving combination chemotherapy.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
- Trial name
- NCT01941173
- Testing
- ziv-aflibercept, leucovorin calcium, irinotecan hydrochloride
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00100841
- Testing
- cetuximab, bevacizumab, oxaliplatin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocarcinoma, Lung Cancer
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus…
- Conditions
- Hepatocarcinoma, Lung Cancer, Melanoma, Renal Cancer
- Trial name
- NCT03755739
- Testing
- Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Rectal Cancer
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer
The treatment protocol proposed in this study is to perform short-term radiation therapy and 4 cycles of FOLFOX chemotherapy for neoadjuvant treatment of locally advanced rectal cancer.
- Trial name
- SOLAR (NCT05673772)
- Testing
- short-course radiotherapy, mFOLFOX6, Chemoradiotherapy
- Where
- 9 sites in South Korea
- Volunteers
- 364 people
- Sponsor
- Kyungpook National University Hospital
Rectal Cancer
Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer
The objective is to evaluate whether the neoadjuvant combination of PD-1 inhibitor tislelizumab and interleukin-2 (IL-2) can significantly enhance the complete response rate (cCR + local excision pCR) and organ preservation rate…
- Trial name
- NCT06504875
- Testing
- Tislelizumab, Interleukin-2, Capecitabine
- Volunteers
- 23 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Rectal Cancer
Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer
This is a nonrandomised pilot trial to establish the role of intravenous cetuximab when added to a schedule of capecitabine plus pelvic radiation in patients who have locally advanced primary resectable rectal cancers.
- Trial name
- XERT (NCT00689702)
- Testing
- cetuximab, capecitabine
- Where
- Slovenia
- Volunteers
- 43 people
- Sponsor
- Institute of Oncology Ljubljana
Rectal Cancer
RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).
To evaluate the efficacy and safety of SOX or mFOLFOX6 as neoadjuvant chemotherapy in patients with resectable rectal cancer, and to identify the more promising regimen.
- Trial name
- NCT02280070
- Testing
- Laboratory test, Medical history and physical examination, BW and height
- Where
- 2 sites in Japan
- Volunteers
- 110 people
- Sponsor
- Clinical Research Support Center Kyush
Rectal Cancer
Efficacy of Ondansetron in LARS Treatment
Patients will be randomized (1:1 ratio) to receive either 4 weeks of Ondansetron followed by 4 weeks of placebo (O-P sequence) or 4 weeks of placebo followed by 4 weeks of Ondansetron (P-O sequence).
- Trial name
- Hodolar (NCT03182179)
- Testing
- Ondansetron 4 MG
- Where
- 2 sites in Switzerland
- Volunteers
- 48 people
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona
Colorectal Cancer, Pancreatic Cancer
Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer
RATIONALE: Determining how patients makes decisions about participating in a clinical trial may help doctors plan clinical trials in which more patients are willing to participate and are satisfied with their decision to…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00478010
- Testing
- counseling intervention, study of socioeconomic and demographic variables, psychosocial assessment and care
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Radiation Oncology, Rectal Cancer
Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer
Preoperative radiotherapy followed by total mesorectal excision (TME) has been recommended as the preferred treatment method for locally advanced rectal cancer.
- Trial name
- NCT03466424
- Testing
- preoperative short-course radiotherapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Fujian Medical University Union Hospital
Rectal Cancer
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
This trial (molecular characterization trial) focuses on rectal cancer, a common cancer that is treated with radiotherapy (RT) as standard of care and represents a setting in which to study the effects of RT on the immune system.
- Trial name
- ROBIN (NCT05943210)
- Testing
- Short Course Radiation Therapy (scRT), Total Mesenteric Excision (TME)
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Weill Medical College of Cornell University
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05462717
- Testing
- RMC-6291
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 222 people
- Sponsor
- Revolution Medicines, Inc.
Rectal Neoplasms
Fish Oil Supplement in Rectal Cancer
Neoadjuvant treatment with radiotherapy (RDT) and chemotherapy (CT) are the treatment of choice for rectal adenocarcinomas in stages II and III. This results currently in pathologic complete response in 10% to 30% of cases.
- Trial name
- NCT02534389
- Testing
- omega-3 fish oil
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Rectal Cancer
1. SAFE-AI ONCO-TRACK: Multimodal GenAI for Early Detection of Minimal Residual Disease and Recurrence in Gastrointestinal Oncology
Current decision tools (TNM, MRI/PET, CEA, and other serum markers, as well as single-marker genomics) are insufficiently predictive of responders, fail to detect early MRD in many cases, and rarely connect molecular biology to…
- Trial name
- ONCO-TRACK (NCT07189520)
- Testing
- Artificial Intelligence
- Volunteers
- 700 people
- Sponsor
- Università Politecnica delle Marche
Gastric Cancer, Colon Cancer
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer
- Trial name
- NCT06006390
- Testing
- CEA-targeted CAR-T cells
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Locally Advanced Rectal Cancer
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.
The Efficacy and Safety of Long-Course Preoperative Chemoradiotherapy Combined with Consolidation or Induction NALIRIFOX Chemotherapy in the Treatment of Locally Advanced Rectal Cancer: A Prospective, Multicenter, Phase II Study.
- Trial name
- NCT06894797
- Testing
- Concurrent Chemoradiotherapy（Radiation + Capecitabine）, irinotecan hydrochloride liposome injection, Oxaliplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Peking University Cancer Hospital & Institute
Rectal Cancer, Surgery
Safety and Efficacy Study of Single-port Robotic Versus Multi-port Robotic Radical Rectal Cancer Surgery
This study is designed to evaluate the safety and efficacy of single-port robotic surgery compared to multi-port robotic surgery for rectal cancer.
- Trial name
- NCT06943690
- Testing
- Single-port robotic surgery, Multi-port robotic surgery
- Where
- 4 sites in China
- Volunteers
- 212 people
- Sponsor
- Ruijin Hospital
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
This study is a single-arm, prospective, phase II clinical study to evaluate the efficacy and safety of preoperative short-course radiotherapy combined with ivonescimab and chemotherapy + total mesorectal excision(TME) surgery in…
- Trial name
- NCT06760520
- Testing
- Ivonescimab (SMT112 or AK112) Injection
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Rectal Cancer, Locally Advanced Rectal Cancer
A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue
This clinical study investigates the anti-inflammatory and anti-cancer properties of a high-bioavailability formulation of curcumin (BCM-95) in patients with mid-to-low rectal cancer receiving neoadjuvant chemoradiotherapy…
- Conditions
- Rectal Cancer, Locally Advanced Rectal Cancer, Radiation-Induced Enteritis, Radiation Proctitis
- Trial name
- BCMRECRAD (NCT07248020)
- Testing
- Curcumin (BCM-95®)
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- Chang Gung Memorial Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.